Menorrhagia (Heavy Menstrual Bleeding): Causes, Symptoms, Treatment & Prevention

Clinicians historically used menorrhagia for excessively heavy menstrual bleeding; international consensus now favours the symptomatic label heavy menstrual bleeding (HMB) nested under the broader abnormal uterine bleeding (AUB) umbrella, with “HMB” or AUB-H indicating volume or duration that overwhelms usual coping, pads/tampons, or haemoglobin reserve. Nurses differentiate regular heavy cycles from acute heavy uterine bleeding (HMB that risks instability) and from intermenstrual or post-coital bleeding patterns that imply alternate COEIN mechanisms—documentation should use consistent descriptors because pathway triggers differ.

Pathophysiology is heterogeneous: focal lesions increase endometrial surface or impair contraction (submucosal fibroids, polyps), adenomyosis disrupts myometrial haemostasis, ovulatory dysfunction yields unpredictable breakthrough bleeding, coagulopathies including von Willebrand disease prolong platelet plug stability, while primary endometrial fragility can exist without structural imaging findings. Iatrogenic sources—anticoagulants, copper IUD, some antipsychotics—must stay in every reconciliation because they can convert mild HMB into transfusion-relevant loss.

FIGO’s PALM–COEIN taxonomy standardises causes of AUB for people of reproductive age. PALM denotes structural disease confirmed (or reasonably inferred) by imaging or histopathology; COEIN lists functional or medical contributors that imaging may not “see.” PALM entities interact with ultrasound and hysteroscopy pathways, whereas COEIN entities often need endocrine, coagulation, medication review, or targeted endometrial assessment.

↔On a small screen, swipe or scroll sideways to see the full table.

HMB is both objective (iron deficiency, haemoglobin fall) and subjective (flooding, work absence). Bedside nurses translate “heavy” into quantifiable data whenever possible: hours between pad changes, clot dimensions, syncope, or stigmata of fatigue from microcytic anaemia.

Typical presentation

• Progressive increase in days of bleeding, pad saturation within 1–2 hours, passage of large clots, nocturnal “gushing,” doubling products, or menstrual cups requiring unusually frequent emptying.
• Predictable cyclic heavy flow with superimposed dysmenorrhoea when adenomyosis or fibroids contribute; flooding may worsen over several cycles.
• Exhaustion, breathlessness on exertion, pallor, pica, restless legs—signals of iron deficiency alongside heavier flow.

Atypical or high-risk patterns

• Intermenstrual or post-coital bleeding—raises priority for cervical and endometrial evaluation beyond “pure HMB.”
• Acute torrential bleeding with hypotension, resting tachycardia, or postural changes—shift from outpatient pathway to emergency haemorrhage protocols.
• Heavy bleeding from menarche in an adolescent—consider inherited bleeding disorder co-screening per local haematology guidance.
• Perimenopause with erratic heavy episodes—still warrants malignancy safety netting if risk factors accumulate.

Heavy menstrual bleeding rarely boils down to one mechanism; nurses integrate PALM–COEIN with reproductive life-stage. Structural drivers—fibroids, polyps, adenomyosis—dominate imaging-positive pathways, while endometriosis more often couples pain than isolated volume bleeding yet may coexist. PCOS-linked anovulation thins the endometrium unpredictably, triggering heavy episodic bleeds after prolonged oestrogen exposure.

Modifiable contributors

• Anticoagulant and antiplatelet therapy—dose changes often precede frank HMB.
• Hormonal contraception omissions, drug interactions lowering progestin levels, copper IUD early after insertion (document temporal relation before attributing to unrelated pathology).
• Excess adipose tissue amplifies oestrogen peripheral conversion—synergistic with PCOS and metabolic syndrome.

Non-modifiable or intrinsic risk

• Inherited coagulopathies (von Willebrand disease common among bleeding disorder referrals for menorrhagia).
• Gravid or postpartum history (uterine atony prior does not predict chronic HMB, but retained tissue or endometritis acute episodes belong on discharge review timelines).
• Family clustering of bleeding diathesis or early hysterectomy for “hormonal problems.”

Clinical assessment

Capture menstrual calendars (days of bleeding, clots, nocturnal soaking), pregnancy intent, contraception method, anticoagulant use, family history of hysterectomy or bleeding disorders, and cervical screening status. Heavy menstrual bleeding as a symptom concept complements PALM–COEIN coding when educating patients about what you are investigating. Measure heart rate and orthostatic blood pressure when volume depletion suspected.

Laboratory investigations

• CBC for haemoglobin trending; interpret against hydration status.
• Ferritin with CRP/inflammation context—iron deficiency may precede overt anaemia.
• Pregnancy exclusion via urine or serum hCG when any chance of conception exists—see pregnancy test (hCG) overview.
• Thyroid-stimulating hormone, prolactin, and androgens when oligomenorrhoea suggests endocrine drivers beyond isolated HMB.
• Coagulation screening and referral when clinical suspicion of inherited bleeding disorder is high.

Imaging

Transvaginal ultrasound is first-line for uterine anatomy; pelvic ultrasound may supplement when transabdominal views add value. Sonohysterography or MRI escalation follows local gynecology algorithms when focal lesions remain occult yet symptoms persist.

Diagnostic criteria / scoring systems used in practice

Pictorial blood loss assessment charts assist research definitions, but pragmatically many services treat HMB that interferes with physical, emotional, social, or material quality of life—align documentation with FIGO AUB nomenclature so theatre and imaging colleagues interpret referrals consistently. Endometrial sampling hinges on age, risk factors for hyperplasia, and failed medical therapy rather than a single universal haemoglobin cutoff.

Heavy periods are often mistaken for “normal variation” or stress-related dysfunction—yet sustained flow volume differences predict pathology often enough to warrant systematic workup. Use the matrix to separate mimics that demand distinct escalation.

↔On a small screen, swipe or scroll sideways to see the full table.

Shared decision-making matches efficacy, side-effect tolerance, fertility desire, and bleeding acuity. Acute haemodynamic compromise temporarily borrows inpatient protocols (IV oestrogen bundles, high-dose progestogens, tranexamic acid) per specialist orders—this section centres stable outpatient chronic HMB while highlighting rescue triggers.

First-line medical management

• Levonorgestrel-releasing intrauterine system when uterine cavity suitable—often most effective for idiopathic HMB and adenomyosis-predominant patterns.
• Combined oral contraceptive pills or cyclic progestogens (norethindrone, medroxyprogesterone) when estrogen is not contraindicated.
• Antifibrinolytic therapy with tranexamic acid during menses for many non-pregnant adults when no thrombosis contraindication—usually clinician-directed dosing.
• NSAID classes (e.g., mefenamic acid where licensed) around menstruation can reduce blood loss while relieving dysmenorrhoea—respect renal, GI, and cardiovascular cautions.

Second-line and procedural options

• Endometrial ablation when fertility complete and structural pathology excluded or addressed.
• Myomectomy, uterine artery embolisation, or hysterectomy for refractory fibroid-related bleeding—coordination via MDT.
• Iron deficiency repletion with ferrous sulfate or IV iron protocols when oral therapy fails (see condition monograph for monitoring).

Special populations

• Adolescents: reassure where appropriate but screen bleeding disorders; involve guardians in safety-netting.
• Perimenopause: irregular cycles plus heavy flow—maintain malignancy vigilance per age cutoffs.
• Anticoagulated patients: liaise with anticoagulation clinics before NSAIDs; escalate procedural options earlier when medical therapy limited.

Workflow thinking converts “heavy periods” into accountable steps: quantify blood loss trend → correct anaemia → match therapy to PALM–COEIN category → define failure timelines → document escalation ownership.

• Monitoring cadence: repeat CBC and ferritin 8–12 weeks after initiating iron or hormonal therapy when bleeding stabilises; sooner if symptoms worsen.
• Treatment failure criteria: ongoing objective HMB after 3–6 months of compliant first-line therapy—or earlier with severe impact—prompts specialist reassessment.
• Referral thresholds: imaging-suspected submucosal fibroid, acute haemorrhage despite oral therapy, need for endometrial histology, or fertility-preserving surgery discussion.
• Documentation: clot size comparisons, pad counts, orthostatic vitals, transfusion episodes, and blood transfusion administration nursing checks when applicable.
• MDT roles: gynaecology, haematology, anaesthesia for complex cases; pharmacist for anticoagulation and DDIs.

Clinical decision flow (shift-ready)

1. Stable outpatient with chronic HMB → baseline CBC/iron studies + TV imaging per pathway.
2. Tachycardic, hypotensive, or syncopal → emergency evaluation, large-bore access, laboratory coagulation panel, consider acute medical therapy bundle.
3. Postmenopausal bleeding or age >45 with new AUB → urgent clinic escalation for endometrial assessment per ACOG-style criteria.
4. Menarche-age flooding with bruising history → coagulation screening before dismissing as “normal teen periods.”

Bedside monitoring checklist

• Serial haemoglobin if admission-level bleeding; track urine output if aggressive resuscitation.
• Watch for NSAID–anticoagulant interaction risks when patients self-medicate dysmenorrhoea.
• Psychological distress screening—HMB drives absenteeism and shame; signpost advocacy resources where available.

• Iron-deficiency anaemia with reduced exercise tolerance, cognition impacts, and perioperative risk if surgery eventually required.
• Increased thromboembolic consideration when high-estrogen rescue therapy used for acute bleeding—document mobility and VTE prophylaxis per facility policy.
• Healthcare avoidance and mental health sequelae from cyclical debilitation.
• Malignancy overlooked when heavy bleeding normalised in higher-BMI patients—maintain endometrial safeguards.

Clinician-facing prevention targets modifiable drivers: optimise anticoagulant dosing with specialist review when HMB emerges, counsel on consistent hormonal method use once initiated, and ensure timely management of fibroid growth before secondary anaemia entrenches—no single lifestyle intervention abolishes structural disease, yet weight stabilisation in PCOS phenotype reduces oestrogen excess swings.

With guideline-concordant therapy, many patients achieve acceptable bleeding within three menstrual cycles; LNG-IUS trials historically report high satisfaction for idiopathic HMB though early irregular bleeding requires counselling. Structural disease prognosis hinges on lesion control; coagulopathy outcomes improve when factor or haemostatic therapies align with gynecology planning.

Communication and equity

Use neutral language (“menstrual bleeding” vs dismissive tone) and recognise cultural taboos that delay help-seeking; offer interpreter access and private medication teaching when discussing intrauterine options.

Medication coordination

Clarify over-the-counter NSAID stack risks with prescribed anticoagulants; confirm patient understanding of tranexamic acid timing with meals and contraindications.

Escalation triggers

• Systolic BP under 90 mmHg, heart rate >120 bpm at rest, confusion, or ongoing large clots with haemodynamic symptoms—activate emergency pathway.
• Hb below institutional transfusion threshold with active bleeding or symptomatic anaemia—notify medical team for blood product plan.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items rotate Priority FIRST, SATA, deterioration triage, multi-patient sorting, ordered workup, matrix matching, and cloze drops around heavy menstrual bleeding, PALM–COEIN reasoning, and acute haemorrhage escalation.